Radius Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Radius Health, Inc.
Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.
Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
With at least two potential candidates being touted as potential best-in-class by their sponsors, the oral SERD market is shaping up to be highly competitive. Sanofi has taken an early lead in expanding the scope of its Phase III breast cancer program.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- NuVios, Inc.